Skye Bioscience (SKYE) Liabilities and Shareholders Equity (2012 - 2026)

Skye Bioscience (SKYE) has reported Liabilities and Shareholders Equity for 15 consecutive years, with $19.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 70.03% year-over-year to $19.4 million; the TTM figure through Mar 2026 stood at $141.2 million (down 53.9% YoY), while the FY2025 annual figure was $28.3 million, down 61.09% from the prior year.
• Liabilities and Shareholders Equity eased to $19.4 million in Q1 2026 per SKYE's latest filing, from $28.3 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $94.8 million in Q1 2024 and bottomed at $2.2 million in Q2 2023.
• Historically, Liabilities and Shareholders Equity has averaged $35.3 million across 5 years, with a median of $19.4 million in 2026.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity sank 75.45% — and 2024, when it jumped 3802.67%.
• Skye Bioscience's Liabilities and Shareholders Equity stood at $9.1 million in 2022, then soared by 31.05% to $11.9 million in 2023, then soared by 509.39% to $72.8 million in 2024, then sank by 61.09% to $28.3 million in 2025, then plunged by 31.42% to $19.4 million in 2026.
• Business Quant data shows SKYE's Liabilities and Shareholders Equity at $19.4 million in Q1 2026, $28.3 million in Q4 2025, and $41.3 million in Q3 2025.